NBM-BMX
/ NatureWise Biotech & Medicals Corp
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 23, 2025
FDA Grants Orphan Drug Designation to NBM-BMX for Uveal Melanoma
(NovelWise Press Release)
Orphan drug • Uveal Melanoma
October 20, 2025
NovelWise Pharmaceutical Corporation…announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for NBM-BMX, a selective HDAC8 inhibitor, for the treatment of metastatic uveal melanoma (mUM)
(NovelWise Press Release)
- "The designation was granted based on preclinical data in uveal melanoma models, as well as safety and dose information from previous Phase I clinical studies...NovelWise plans to initiate site initiation visits (SIVs) by late 2025, followed by a Phase Ib/II clinical trial evaluating NBM-BMX as monotherapy in patients with metastatic uveal melanoma."
Fast track • Trial status • Uveal Melanoma
August 25, 2023
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
(clinicaltrials.gov)
- P1/2 | N=79 | Recruiting | Sponsor: NatureWise Biotech & Medicals Corporation
Combination therapy • Monotherapy • New P1/2 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1